[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342910-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-342910-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","clinical-and-molecular-predictors-of-very-late-recurrence-in-oestrogen-receptor-positive-breast-cancer-patients","Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients","","Risk of recurrence after primary oestrogen receptor-positive (ER+) breast cancer persists for at least two decades, yet predictors beyond 10 years remain insufficient. This study compares clinical, pathological, and molecular features between very late recurrence (VLR) cases and controls without recurrence, using the BC360 NanoString Panel and an 87-gene targeted-exome panel, with METABRIC used for external validation.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-and-molecular-predictors-of-very-late-recurrence-in-oestrogen-receptor-positive-breast-cancer-patients/342910/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-and-molecular-predictors-of-very-late-recurrence-in-oestrogen-receptor-positive-breast-cancer-patients/342910.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was the study aim regarding very late recurrence in ER+ breast cancer?","Question",{"text":62,"@type":63},"To identify clinical and molecular features associated with recurrence risk occurring after 10 years in oestrogen receptor-positive breast cancer patients.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were patients grouped in the Very Late Recurrence (VLR) cohort?",{"text":67,"@type":63},"Cases had recurrence between 10 and 20 years, while controls had no recurrence by 20 years.",{"name":69,"@type":60,"acceptedAnswer":70},"What key findings differentiated VLR cases from controls?",{"text":71,"@type":63},"VLR cases showed larger tumours and higher node positivity, while cell cycle and proliferation genes were strongly expressed in VLR cases; immune-related genes and cell cycle inhibitors were more highly expressed in controls, though many differences were not significant after correction.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},342910,1792168947,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Breast Cancer Research and Treatment (2024) 206:195–205  \n[https://doi.org/10.1007/s10549-024-07311-z](https://doi.org/10.1007/s10549-024-07311-z)  \nClinical and molecular predictors of very late recurrence in oestrogen receptor‑positive breast cancer patients  \nJuliet Richman1 · Gene Schuster1,2 · Richard Buus1,2 · Elena Lopez‑Knowles1,2 · Mitch Dowsett1  \nReceived: 3 January 2024 / Accepted: 22 March 2024 / Published online: 6 May 2024 © The Author(s) 2024  \nAbstract  \nBackground Risk of recurrence from primary ER+ breast cancer continues for at least 20 years. We aimed to identify clinical and molecular features associated with risk of recurrence after 10 years.  \nMethods ER+ breast cancers from patients with and without recurrence were analysed with the BC360 NanoString Panel and an 87 gene targeted-exome panel. Frequency of clinical, pathologic and molecular characteristics was compared between cases (recurred between 10 and 20 years) and controls (no recurrence by 20 years) in the Very Late Recurrence (VLR) cohort. Analogous data from METABRIC were examined to confirm or refute findings.  \nResults VLR cases had larger tumours and higher node positivity. Both VLR and METABRIC cases had higher clinical treatment score at 5 years (CTS5) . There was a trend for fewer GATA3 mutations in cases in both VLR and METABRIC but no statistically significant differences in mutation frequency. Cell cycle and proliferation genes were strongly expressed in VLR cases. Immune-related genes and cell cycle inhibitors were highly expressed in controls. Neither of these changes were significant after correction for multiple testing.  \nConclusions Clinicopathologic features are prognostic beyond 10 years. Conversely, molecular features, such as copy number alterations, TP53 mutations and intrinsic subtype which have early prognostic significance, have little prognostic value after 10 years.  \nKeywords Breast cancer · Oestrogen receptor · CTS5 · Very late recurrence  \nBackground  \nBreast cancer patients with oestrogen receptor-negative (ER-) disease that recur, mostly do so within the first 10 years of follow-up [1] . In contrast, ER+ breast cancer has an almost linear risk of recurrence up to 20 years from diagnosis [2]. For ER+ disease, standard clinicopathologic features of early recurrence appear to maintain at least some of their significance for late recurrence and one integrative prognostic tool, the CTS5 (Clinical Treatment Score after 5 years) has been developed to estimate risk between 5 and 10 years after diagnosis in the absence of endocrine treatment beyond 5 years [3] . It is also clear that while some genomic profiling  \n* Juliet Richman [julietrichman@doctors.org.uk](julietrichman@doctors.org.uk)  \n1 Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK  \n2 Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK  \ntests maintain some prognostic significance out to 10 years, this differs between the tests [4, 5] . Additionally, over the period between 5 and 10 years after diagnosis, increased recurrences have been reported to occur in patients with tumours with high levels of both oestrogen-responsive and proliferation-associated genes [6, 7] .  \nOver recent years, at 5 years from diagnosis, women have had the option to continue their endocrine therapy (ET) fora further 5 years because of trial data showing the overall benefit of this for reducing recurrence risk [8–11] . This decision is usually made purely on the basis of clinicopathologic features of the primary tumour and patient factors. Given a potentially life-long risk of recurrence and positive data from one clinical trial of endocrine therapy beyond 10 years [11], there remains a need to distinguish those that have a significant risk of recurrence even after completing 10 years of ET.  \nDespite the long natural history of ER+ breast cancer, little is known about the molecular features that predict for recur","cbCaimZMXeadeeEf","https://ap.wps.com/l/cbCaimZMXeadeeEf","pdf",1219397,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n# Methods\n## Study participants","[{\"question\":\"What was the study aim regarding very late recurrence in ER+ breast cancer?\",\"answer\":\"To identify clinical and molecular features associated with recurrence risk occurring after 10 years in oestrogen receptor-positive breast cancer patients.\"},{\"question\":\"How were patients grouped in the Very Late Recurrence (VLR) cohort?\",\"answer\":\"Cases had recurrence between 10 and 20 years, while controls had no recurrence by 20 years.\"},{\"question\":\"What key findings differentiated VLR cases from controls?\",\"answer\":\"VLR cases showed larger tumours and higher node positivity, while cell cycle and proliferation genes were strongly expressed in VLR cases; immune-related genes and cell cycle inhibitors were more highly expressed in controls, though many differences were not significant after correction.\"}]","Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients | PDF",1790048773,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/416e28f6117df7ff4de79141d76025a1.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec7c258d1308b5fc8bc2c4b390a1ff3d.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/485c96d3de4c230caf296a826f0d1ed6.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc2f9298879fd311a8e765f57966f907.webp",980,1301]